Rapamycin targeting mTOR and hedgehog signaling pathways blocks human rhabdomyosarcoma growth in xenograft murine model
Authors:
- Jianmin XuJXJianmin Xu
- Ritesh K. SrivastavaRSRitesh K. Srivastava
- Levy KopelovichLKLevy Kopelovich
- Joseph G. PresseyJPJoseph G. Pressey
- Mohammad AtharMAMohammad Athar
- 1 June 2013
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 435 (4) , 557-561
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcomaOncogene, 2010
- Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and CancerCancer Research, 2010
- Fusion Gene-Negative Alveolar Rhabdomyosarcoma is Clinically and Molecularly Indistinguishable from Embryonal RhabdomyosarcomaJournal of Clinical Oncology, 2010
- Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975‐2005Cancer, 2009
- Molecular Classification of Rhabdomyosarcoma—Genotypic and Phenotypic Determinants of DiagnosisThe American Journal of Pathology, 2009
- Targeting the molecular target of rapamycin (mTOR)Current Opinion in Oncology, 2004
- Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancerBritish Journal of Cancer, 2004
- Age is an independent prognostic factor in rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children's oncology groupPediatric Blood & Cancer, 2003
- Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic DiseaseJournal of Clinical Oncology, 2001
- The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS‐I Through IRS‐IV Studies as Background for the Current IRS‐V Treatment ProtocolsSarcoma, 2001